Non-Hodgkin Lymphoma

Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL 3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Shah • 15 Feb 2023
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy 5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL 1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL 3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda • 11 Dec 2022
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma 1:00
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma
Mazyar Shadman • 9 Dec 2022
LMY-920 in non-Hodgkin lymphoma 1:58
LMY-920 in non-Hodgkin lymphoma
Jeff Liter • 27 Jan 2022
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1 2:13
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1
Anna Sureda • 9 Feb 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies 3:30
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
The future of CAR T-cell therapy in lymphoma 2:15
The future of CAR T-cell therapy in lymphoma
Anna Sureda • 9 Feb 2021
Liso-cel for R/R large B-cell lymphoma 1:44
Liso-cel for R/R large B-cell lymphoma
Ulrich Jäger • 9 Feb 2021
CART19-BE-01: ARI-0001 in CD19+ malignancies 8:17
CART19-BE-01: ARI-0001 in CD19+ malignancies
Valentín Ortiz-Maldonado • 11 Oct 2020
Real-world efficacy & safety data: CAR-T in DLBCL 3:05
Real-world efficacy & safety data: CAR-T in DLBCL
Matthew Frigault • 1 Sep 2020
Challenges associated with CAR T-cell production 1:45
Challenges associated with CAR T-cell production
Valentín Ortiz-Maldonado • 1 Sep 2020
Tocilizumab: CAR T-cell therapy in DLBCL 2:18
Tocilizumab: CAR T-cell therapy in DLBCL
Matthew Frigault • 1 Sep 2020
Selecting DLBCL patients for CAR T-cell therapies 4:28
Selecting DLBCL patients for CAR T-cell therapies
Anna Sureda • 1 Sep 2020
The content of VJRegenMed is intended for healthcare professionals